23/03/2022 - General information
The European Research Network on Signal Transduction (ERNEST), of which IMIM is a member, has created an Emergency Fund for Ukrainian researchers. Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) are eligible to apply for this funding. For more information you can contact Jana Selent (vice-chair of the ERNEST - Cost Action 18133) or visit this website
17/02/2022 - General information
An IMIM-Hospital del Mar research project aimed at analyzing the mechanisms that generate resistance to immunotherapy treatment in metastatic breast cancer has been selected by the Metastatic Breast Cancer Association in the third edition of this award. The project, headed by doctors Toni Celià-Terrassa and Joan Albanell, will receive 100,000 euros for its development. This afternoon saw the presentation of the III M. Chiara Giorgetti Award for research into metastatic breast cancer. This year it recognises a project from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), led by doctors Toni Celià-Terrassa and Joan Albanell. The award is promoted by the Metastatic Breast Cancer patients' association and involves a prize of 100,000 euros, 25,000 euros of which are provided by the AMAMA association.
Més informació "M. Chiara Giorgetti Award for a Hospital del Mar Medical Research Institute project"
14/02/2022 - General information
In addition, 71% of them claim to have a poor quality of life due to epileptic seizures, according to a study carried out by Hospital del Mar's Epilepsy Unit. Women suffer higher levels of depression and anxiety, as well as a poorer quality of life, compared to men. The results obtained raise the issue of how to address these factors as triggers of epileptic seizures. This is the largest study to date analysing psychiatric comorbidities in patients with this type of pathology. The work has been published in the journal Frontiers in Neurology. People diagnosed with treatment-resistant epilepsy have high levels of depression and anxiety, as well as a poor quality of life, according to a study published in the journal Frontiers in Neurology by Hospital del Mar's Epilepsy Unit . In fact, half of these patients suffer from depression and anxiety and more than 70% claim to have a poor quality of life. This fact suggests that a global approach to these patients should be evaluated, taking into account the psychiatric aspects of their pathology to try to control their epileptic seizures.
10/02/2022 - General information
The Hospital del Mar Medical Research Institute and Hospital del Mar are once again supporting the International Day of Women and Girls in Science, raising awareness of their work and trying to encourage new vocations. In the case of the IMIM, just over half of the research positions are held by women. In the 21st century, women who decide to pursue a career in the various fields of science often receive smaller research grants than their male colleagues. They hold only 12% of the positions in national science academies, while they account for a third of all researchers. Realities that make an initiative like the International Day of Women and Girls in Science and campaigns such as She Inspired Me more necessary than ever.
Més informació "Towards full and equal access to and participation in science for women and girls"
11/02/2022 - General information
The head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute, was appointed to this body, which is part of the European Medicines Agency (EMA), last month. The European Medicines Agency (EMA) has selected Dr. Juan Pablo Horcajada, head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute (IMIM) as a member of its Scientific Advisory Group on Infectious Diseases. This is a body comprising experts in this field from several European countries, chosen by the agency after a selection process, following a proposal from the national medicines agencies.
31/01/2022 - General information
Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.
28/01/2022 - General information
The renowned chef gave an online session in which she explained that it is possible to eat well and healthily and still enjoy food. The talk, organised by the Hospital del Mar Medical Research Institute's Neurosciences programme, is part of the cognitive and social stimulation sessions for volunteers in the PENSA project on the prevention of cognitive impairment. Can you eat healthily and still get excited about what you eat? The answer is yes. This was explained by Ada Parellada, the chef and director of Restaurant Semproniana and 2016 Creu de Sant Jordi winner, who this morning visited the facilities at the Hospital de Mar Medical Research Institute (IMIM) as a guest of the Institute's Neuroscience Programme. Her visit was part of the PENSA project, promoted by the programme, in collaboration with the Barcelonaβeta Brain Research Centre from the Pasqual Maragall Foundation.
26/01/2022 - General information
The technique achieves good results in terms of toxicity, the preservation of the physical appearance and patient ratings when used for partial breast irradiation compared to its use in combination with large doses of fractionated whole-breast irradiation. Patients with early-stage breast cancer more positively evaluate treatment with partial intraoperative radiotherapy of the breast than the approach that uses the same technique in combination with whole-breast irradiation divided into large doses. This is highlighted in a study published in the journal Clinical and Translational Oncology, led by the Radiation Oncology Service and the Functional Breast Pathology Unit at Hospital del Mar as well as researchers in the Radiation Oncology Research Group at the Hospital del Mar Medical Research Institute.
Més informació "Partial intraoperative radiotherapy in breast cancer, more highly rated by patients"
25/01/2022 - General information
A study by CiSAL and CIBERESP shows that, once they have returned to work, they work at a lower rate than those who have not suffered from the disease. Men and women who had no sick leave or who were on sick leave for other illnesses were at least 9% more likely to continue working compared to workers who took cancer-related sick leave, according to this study carried out in Catalonia and published in 'Scientific Reports'. Not being able to work when you can and want to leads to a loss of self-esteem and social relationships, which can make recovering from cancer psychologically difficult", explains Fernando G. Benavides, the coordinator of the study.
18/01/2022 - General information
The predoctoral researcher Lilian Boll from the Evolutionary Genomics Research Group of the GRIB (IMIM-UPF) has obtained one of the 65 grants of the INPhINIT PhD Program of La Caixa Foundation for her project "Identification of neo-epitopes in cancer derived from non-canonical proteins and their potential use in immunotherapy" to study neoantigens. Neoantigens are tumor-specific antigens generated by mutations in tumor cells, which are only expressed in tumor cells. "One of the approaches in immunotherapy is to block cellular checkpoints so that the immune system recognizes tumor cells by their neoantigens," explains Lilian Boll.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
